共同药业(300966) - 2024 Q3 - 季度财报

Major Financial Data Major Accounting Data and Financial Indicators The company's operating revenue for Q3 2024 increased by 12.24% year-on-year, but net profit attributable to shareholders significantly decreased by 270.23% year-on-year, resulting in a net loss year-to-date, while net cash flow from operating activities significantly grew by 891.96% Major Accounting Data and Financial Indicators for Q3 2024 and Year-to-Date | Indicator | Current Period (RMB) | YoY Change in Current Period | Year-to-Date (RMB) | YoY Change Year-to-Date | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 131,567,562.52 | 12.24% | 365,389,573.73 | -5.10% | | Net Profit Attributable to Shareholders of Listed Company | -9,043,624.61 | -270.23% | -14,162,211.34 | -162.16% | | Net Profit Attributable to Shareholders of Listed Company, Excluding Non-recurring Gains and Losses | -9,843,643.50 | -399.98% | -14,770,482.06 | -190.91% | | Net Cash Flow from Operating Activities | -- | -- | 93,276,360.45 | 891.96% | | Basic EPS (RMB/share) | -0.08 | -256.90% | -0.12 | -160.00% | | Weighted Average Return on Net Assets | -0.96% | -1.52% | -1.50% | -3.92% | | End of Current Period | End of Last Fiscal Year | Change from End of Last Fiscal Year | | | | Total Assets | 2,697,253,195.02 | 2,447,740,699.18 | 10.19% | | | Total Equity Attributable to Shareholders of Listed Company | 938,227,543.92 | 952,749,525.16 | -1.52% | | Non-recurring Gains and Losses and Amounts The company's year-to-date non-recurring gains and losses totaled RMB 608,300, primarily from government subsidies and other non-operating income, while disposal of non-current assets resulted in a loss Non-recurring Gains and Losses and Amounts Year-to-Date | Item | Amount for Current Period (RMB) | Amount Year-to-Date (RMB) | Description | | :--- | :--- | :--- | :--- | | Gains/Losses from Disposal of Non-current Assets | -254,002.11 | -226,823.44 | | | Government Subsidies Recognized in Current Period P&L | 517,201.97 | 1,905,200.29 | | | Other Non-operating Income and Expenses Apart from the Above | 2,095,645.97 | 461,475.94 | | | Less: Income Tax Impact | 836,808.75 | 805,552.18 | | | Minority Interests Impact (After Tax) | 722,018.19 | 726,029.89 | | | Total | 800,018.89 | 608,270.72 | -- | - The company classifies individual income tax withholding refunds, amortization of asset-related government subsidies, and VAT additional deductions as recurring gains and losses, given their continuous and non-incidental nature[5] Changes and Reasons for Major Accounting Data and Financial Indicators During the reporting period, several items in the company's balance sheet, income statement, and cash flow statement experienced significant changes, primarily influenced by capitalization of fundraising projects, new bank borrowings, associate company profits, increased government subsidies, and exchange rate fluctuations Items with Significant Changes in Balance Sheet and Reasons Major Balance Sheet Changes and Reasons | Item | September 30, 2024 (RMB) | January 1, 2024 (RMB) | Change Rate | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | | Notes Receivable | 21,645,710.62 | 9,502,405.17 | 127.79% | Primarily due to an increase in endorsed and transferred notes not yet due and not derecognized | | Fixed Assets | 858,214,432.40 | 208,991,308.72 | 310.65% | Primarily due to capitalization of fundraising projects | | Short-term Borrowings | 252,273,011.10 | 110,092,522.22 | 129.15% | Primarily due to new short-term borrowings | | Deferred Income | 141,389,053.67 | 84,327,123.79 | 67.67% | Primarily due to increased government subsidies | | Minority Interests | 93,213,009.15 | 71,026,064.80 | 31.24% | Primarily due to capital increase by co-shareholders of non-wholly owned subsidiary Huahai | Items with Significant Changes in Income Statement and Reasons Major Income Statement Changes and Reasons (Jan-Sep 2024) | Item | Jan-Sep 2024 (RMB) | Jan-Sep 2023 (RMB) | Change Rate | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | | Financial Expenses | 13,470,914.01 | 7,040,056.23 | 91.35% | Primarily due to increased bank borrowings and cessation of capitalization for some borrowing costs | | Investment Income | 382,374.82 | -67,224.74 | 668.80% | Primarily due to profit from associate company Tongxin Pharmaceutical | | Asset Impairment Losses | 6,730,449.33 | -458,723.73 | 1567.21% | Primarily due to reversal of some inventory depreciation provisions | | Non-operating Expenses | 1,921,628.83 | 2,305.01 | 83267.48% | Primarily due to increased donation expenses | Items with Significant Changes in Cash Flow Statement and Reasons Major Cash Flow Statement Changes and Reasons (Jan-Sep 2024) | Item | Jan-Sep 2024 (RMB) | Jan-Sep 2023 (RMB) | Change Rate | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 93,276,360.45 | 9,403,225.49 | 891.96% | Primarily due to increased government subsidies received and cash received from sales of goods | | Net Cash Flow from Financing Activities | 219,882,971.39 | -19,276,386.77 | 1240.69% | Primarily due to increased bank borrowings | | Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,103,231.52 | -83,656.64 | 1418.76% | Primarily due to exchange rate fluctuations | Shareholder Information Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings As of the end of the reporting period, the company had 14,201 common shareholders, with Xi Zubin and Li Minglei as the top two shareholders, holding 31.72% and 11.91% respectively - Total common shareholders at the end of the reporting period were 14,201[10] Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held (shares) | Number of Restricted Shares Held (shares) | | :--- | :--- | :--- | :--- | :--- | | Xi Zubin | Domestic Natural Person | 31.72% | 36,567,000 | 27,425,250 | | Li Minglei | Domestic Natural Person | 11.91% | 13,725,300 | 11,528,250 | | Danjiangkou Gongtong Chuangxin Investment Partnership (Limited Partnership) | Domestic Non-state-owned Legal Person | 4.77% | 5,501,200 | 0 | | Zhejiang Huahai Pharmaceutical Co., Ltd. | Domestic Non-state-owned Legal Person | 2.70% | 3,117,929 | 0 | | Hubei Gaojin Biotechnology Venture Capital Fund Partnership (Limited Partnership) | Domestic Non-state-owned Legal Person | 1.40% | 1,613,185 | 0 | | Zhang Xin | Domestic Natural Person | 1.22% | 1,400,900 | 0 | | Shenzhen Jiajun Lihao Investment Development Co., Ltd. | Domestic Non-state-owned Legal Person | 1.19% | 1,366,700 | 0 | | Jiang Jianjun | Domestic Natural Person | 1.04% | 1,193,625 | 1,193,625 | | Tang Youde | Domestic Natural Person | 0.80% | 925,900 | 0 | | Wang Shanyou | Domestic Natural Person | 0.72% | 826,457 | 0 | - The company's concerted parties at the initial public offering included Xi Zubin, Danjiangkou Gongtong Chuangxin Investment Partnership (Limited Partnership), and Zhang Xin[10] Total Number of Preferred Shareholders and Top 10 Preferred Shareholders' Holdings The company has no preferred shareholders - The company has no preferred shareholders[12] Changes in Restricted Shares At the end of the reporting period, the company's total restricted shares were 40,147,125, with 16,043,850 shares released this period, primarily involving Xi Zubin, Danjiangkou Gongtong Chuangxin Investment Partnership, and Zhang Xin Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (shares) | Restricted Shares Released This Period (shares) | Restricted Shares Increased This Period (shares) | Restricted Shares at End of Period (shares) | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | :--- | | Xi Zubin | 36,567,000 | 9,141,750 | 0 | 27,425,250 | Shares Locked by Senior Management | | Li Minglei | 11,528,250 | 0 | 0 | 11,528,250 | Shares Locked by Senior Management | | Danjiangkou Gongtong Chuangxin Investment Partnership (Limited Partnership) | 5,501,200 | 5,501,200 | 0 | 0 | Not Applicable | | Jiang Jianjun | 1,193,625 | 0 | 0 | 1,193,625 | Shares Locked by Senior Management | | Zhang Xin | 1,400,900 | 1,400,900 | 0 | 0 | Not Applicable | | Total | 56,190,975 | 16,043,850 | 0 | 40,147,125 | -- | Other Significant Matters - No other significant matters in this reporting period[13] Quarterly Financial Statements Financial Statements The company disclosed its consolidated balance sheet, consolidated income statement, and consolidated cash flow statement from the beginning of the year to the end of the reporting period, reflecting the financial position, operating results, and cash flow for the first three quarters Consolidated Balance Sheet Consolidated Balance Sheet Key Data (As of September 30, 2024) | Item | Period-end Balance (RMB) | Period-beginning Balance (RMB) | | :--- | :--- | :--- | | Total Assets | 2,697,253,195.02 | 2,447,740,699.18 | | Total Current Assets | 758,322,380.59 | 869,731,565.50 | | Total Non-current Assets | 1,938,930,814.43 | 1,578,009,133.68 | | Total Liabilities | 1,665,812,641.95 | 1,423,965,109.22 | | Total Equity Attributable to Parent Company Shareholders | 938,227,543.92 | 952,749,525.16 | | Minority Interests | 93,213,009.15 | 71,026,064.80 | | Total Liabilities and Equity | 2,697,253,195.02 | 2,447,740,699.18 | Consolidated Income Statement from Beginning of Year to End of Reporting Period Consolidated Income Statement Key Data (Jan-Sep 2024) | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 365,389,573.73 | 385,037,986.62 | | Total Operating Costs | 407,868,913.77 | 372,954,404.95 | | Operating Profit | -27,240,577.48 | 15,085,471.04 | | Total Profit | -26,329,041.44 | 18,560,673.65 | | Net Profit | -16,527,962.21 | 21,376,634.95 | | Net Profit Attributable to Parent Company Shareholders | -14,162,211.34 | 22,784,477.65 | | Minority Interest Income/Loss | -2,365,750.87 | -1,407,842.70 | | Basic Earnings Per Share | -0.12 | 0.20 | | Diluted Earnings Per Share | -0.12 | 0.20 | Consolidated Cash Flow Statement from Beginning of Year to End of Reporting Period Consolidated Cash Flow Statement Key Data (Jan-Sep 2024) | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 93,276,360.45 | 9,403,225.49 | | Net Cash Flow from Investing Activities | -328,850,334.97 | -310,421,621.20 | | Net Cash Flow from Financing Activities | 219,882,971.39 | -19,276,386.77 | | Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,103,231.52 | -83,656.64 | | Net Increase in Cash and Cash Equivalents | -14,587,771.61 | -320,378,439.12 | | Cash and Cash Equivalents at End of Period | 81,618,387.68 | 94,771,263.76 | Adjustments to Financial Statement Items at the Beginning of the First Year of Adopting New Accounting Standards from 2024 The company adopted new accounting standards from 2024 but had no adjustments to financial statement items at the beginning of the first year of adoption during this reporting period - The company has no adjustments to financial statement items at the beginning of the first year of adopting new accounting standards from 2024[19] Audit Report This quarterly report is unaudited - The company's third-quarter report is unaudited[19]